Subacute cutaneous lupus erythematosus induced by capecitabine: 5‐FU was innocent

References 1 Durbec F, Martin L, Derancourt C, Grange F. Melanoma of the hand and foot: epidemiological, prognostic and genetic features. A systematic review. Br J Dermatol 2012; 166: 727–39. 2 Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007; 60: 32–40. 3 Hsueh EC, Lucci A, Qi K, Morton DL. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer 1999; 85: 383–8. 4 Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986– 2005. Arch Dermatol 2009; 145: 427–34. 5 Aoyagi S, Hata H, Homma E, Shimizu H. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology 2012; 82: 139–46. 6 Matsumoto T, Yokota K, Sawada M et al. Postoperative DAV-IFN-b therapy does not improve survival rates of stage II and stage III melanoma patients significantly. J Eur Acad Dermatol Venereol 2013; 27: 1514–20. 7 Nakamura Y, Ohara K, Kishi A et al. Effects of non-amputative wide local excision on the local control and prognosis of in situ and invasive subungual melanoma. J Dermatol 2015; 42: 1–6.